Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bladder Cancer|Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer
Interventions: DRUG: gemcitabine hydrochloride|DRUG: irinotecan hydrochloride
Sponsor: Northwestern University
Collaborators: National Cancer Institute (NCI)